SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer

05/10/2021 06:48
  • AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program that is showing promise in hard-to-treat breast cancer.
  • The ADC, datopotamab deruxtecan, posted a 43% response rate and five confirmed complete or partial responses among 21 patients with triple-negative breast cancer, according to cohort data from the TROPION-PanTumor01 Phase 1 study presented at the virtual ESMO Breast annual meeting 2021.
  • The majority of those patients were treated with 6-mg doses of the drug, while two received an 8-mg high dose.
  • Five confirmed complete (CR) or partial responses (PR) were also seen, with four additional CR/PRs awaiting confirmation at the time of data cutoff on January 8. A disease control rate of 95% was also observed.
  • Meanwhile, the TNBC cohort reported zero cases of interstitial lung disease.
  • The drug combines an antibody targeting TROP2 that's conjugated using a stable linker with a potent topoisomerase I inhibitor payload. It has a lower drug-to-antibody ratio that Daiichi suggests should both boost cell-killing activity and limit side effects.
  • Price Action: AZN shares are trading 0.8% higher at $54.25 during the premarket session on the last check Monday, while DSNKY shares closed $25.86 on Friday